An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour

Tam C. Ha, Filippo Spreafico, Norbert Graf, Sandro Dallorso, Jeffrey S. Dome, Marcio Malogolowkin, Rhoikos Furtwängler, Juliet P. Hale, Veronica Moroz, David MacHin, Kathy Pritchard-Jones

Research output: Contribution to journalArticle

Abstract

Purpose: To review event-free (EFS) and overall survival (OS) from publications describing outcome for children with relapsed Wilms' tumour. Comparisons are made between those receiving myeloablative high dose chemotherapy with autologous stem-cell rescue (HDT) and those not (NoHDT). Materials and methods: Relevant information was extracted from individual patient or summary data and 3-year EFS and OS rates established. These rates were combined in a weighted manner to derive hazard ratios (HRs). Results: Nineteen publications were identified (5 HDT, 6 NoHDT, 8 both). Pooling all studies suggested an advantage to HDT with a hazard ratio (HR) for EFS of 0.87 (95% confidence interval (CI) 0.67-1.12) and 0.94 (0.71-1.24) for OS. A stratified analysis confined to studies that provided individual patient data on both HDT and NoHDT gave HRs of 0.83 (0.56-1.24) and 0.92 (0.59-1.41). Further, analyses of risk groups, defined by treatment and/or histology prior to first relapse, suggested a HR for EFS of 0.90 (95% CI 0.62-1.31) for those of high and 0.50 (CI 0.31-0.82) for the very high risk patients. Conclusion: The evidence suggests, although there are many caveats since the information summarised here is not from randomised trials, a great deal of uncertainty concerning the role of HDT in patients following relapse after treatment for their Wilms' tumour. For each risk group we propose a randomised trial comparing a standard with a more intensive therapy with specific choice of regimen tailored to the risk group (and co-operative groups) concerned. A synthesis of updated evidence from studies in this overview together with any emerging studies and future trial information will form the basis for future evidence-based clinical decision-making.

Original languageEnglish
Pages (from-to)194-210
Number of pages17
JournalEuropean Journal of Cancer
Volume49
Issue number1
DOIs
Publication statusPublished - Jan 2013

Fingerprint

Wilms Tumor
Confidence Intervals
Publications
Recurrence
Survival
Therapeutics
Uncertainty
Histology
Stem Cells
Survival Rate
Drug Therapy

Keywords

  • High dose chemotherapy
  • Relapsed Wilms' tumour
  • Wilms' tumour

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour. / Ha, Tam C.; Spreafico, Filippo; Graf, Norbert; Dallorso, Sandro; Dome, Jeffrey S.; Malogolowkin, Marcio; Furtwängler, Rhoikos; Hale, Juliet P.; Moroz, Veronica; MacHin, David; Pritchard-Jones, Kathy.

In: European Journal of Cancer, Vol. 49, No. 1, 01.2013, p. 194-210.

Research output: Contribution to journalArticle

Ha, TC, Spreafico, F, Graf, N, Dallorso, S, Dome, JS, Malogolowkin, M, Furtwängler, R, Hale, JP, Moroz, V, MacHin, D & Pritchard-Jones, K 2013, 'An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour', European Journal of Cancer, vol. 49, no. 1, pp. 194-210. https://doi.org/10.1016/j.ejca.2012.07.010
Ha, Tam C. ; Spreafico, Filippo ; Graf, Norbert ; Dallorso, Sandro ; Dome, Jeffrey S. ; Malogolowkin, Marcio ; Furtwängler, Rhoikos ; Hale, Juliet P. ; Moroz, Veronica ; MacHin, David ; Pritchard-Jones, Kathy. / An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour. In: European Journal of Cancer. 2013 ; Vol. 49, No. 1. pp. 194-210.
@article{cf9fa8382fa840be83d919bf149ec6ea,
title = "An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour",
abstract = "Purpose: To review event-free (EFS) and overall survival (OS) from publications describing outcome for children with relapsed Wilms' tumour. Comparisons are made between those receiving myeloablative high dose chemotherapy with autologous stem-cell rescue (HDT) and those not (NoHDT). Materials and methods: Relevant information was extracted from individual patient or summary data and 3-year EFS and OS rates established. These rates were combined in a weighted manner to derive hazard ratios (HRs). Results: Nineteen publications were identified (5 HDT, 6 NoHDT, 8 both). Pooling all studies suggested an advantage to HDT with a hazard ratio (HR) for EFS of 0.87 (95{\%} confidence interval (CI) 0.67-1.12) and 0.94 (0.71-1.24) for OS. A stratified analysis confined to studies that provided individual patient data on both HDT and NoHDT gave HRs of 0.83 (0.56-1.24) and 0.92 (0.59-1.41). Further, analyses of risk groups, defined by treatment and/or histology prior to first relapse, suggested a HR for EFS of 0.90 (95{\%} CI 0.62-1.31) for those of high and 0.50 (CI 0.31-0.82) for the very high risk patients. Conclusion: The evidence suggests, although there are many caveats since the information summarised here is not from randomised trials, a great deal of uncertainty concerning the role of HDT in patients following relapse after treatment for their Wilms' tumour. For each risk group we propose a randomised trial comparing a standard with a more intensive therapy with specific choice of regimen tailored to the risk group (and co-operative groups) concerned. A synthesis of updated evidence from studies in this overview together with any emerging studies and future trial information will form the basis for future evidence-based clinical decision-making.",
keywords = "High dose chemotherapy, Relapsed Wilms' tumour, Wilms' tumour",
author = "Ha, {Tam C.} and Filippo Spreafico and Norbert Graf and Sandro Dallorso and Dome, {Jeffrey S.} and Marcio Malogolowkin and Rhoikos Furtw{\"a}ngler and Hale, {Juliet P.} and Veronica Moroz and David MacHin and Kathy Pritchard-Jones",
year = "2013",
month = "1",
doi = "10.1016/j.ejca.2012.07.010",
language = "English",
volume = "49",
pages = "194--210",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "1",

}

TY - JOUR

T1 - An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour

AU - Ha, Tam C.

AU - Spreafico, Filippo

AU - Graf, Norbert

AU - Dallorso, Sandro

AU - Dome, Jeffrey S.

AU - Malogolowkin, Marcio

AU - Furtwängler, Rhoikos

AU - Hale, Juliet P.

AU - Moroz, Veronica

AU - MacHin, David

AU - Pritchard-Jones, Kathy

PY - 2013/1

Y1 - 2013/1

N2 - Purpose: To review event-free (EFS) and overall survival (OS) from publications describing outcome for children with relapsed Wilms' tumour. Comparisons are made between those receiving myeloablative high dose chemotherapy with autologous stem-cell rescue (HDT) and those not (NoHDT). Materials and methods: Relevant information was extracted from individual patient or summary data and 3-year EFS and OS rates established. These rates were combined in a weighted manner to derive hazard ratios (HRs). Results: Nineteen publications were identified (5 HDT, 6 NoHDT, 8 both). Pooling all studies suggested an advantage to HDT with a hazard ratio (HR) for EFS of 0.87 (95% confidence interval (CI) 0.67-1.12) and 0.94 (0.71-1.24) for OS. A stratified analysis confined to studies that provided individual patient data on both HDT and NoHDT gave HRs of 0.83 (0.56-1.24) and 0.92 (0.59-1.41). Further, analyses of risk groups, defined by treatment and/or histology prior to first relapse, suggested a HR for EFS of 0.90 (95% CI 0.62-1.31) for those of high and 0.50 (CI 0.31-0.82) for the very high risk patients. Conclusion: The evidence suggests, although there are many caveats since the information summarised here is not from randomised trials, a great deal of uncertainty concerning the role of HDT in patients following relapse after treatment for their Wilms' tumour. For each risk group we propose a randomised trial comparing a standard with a more intensive therapy with specific choice of regimen tailored to the risk group (and co-operative groups) concerned. A synthesis of updated evidence from studies in this overview together with any emerging studies and future trial information will form the basis for future evidence-based clinical decision-making.

AB - Purpose: To review event-free (EFS) and overall survival (OS) from publications describing outcome for children with relapsed Wilms' tumour. Comparisons are made between those receiving myeloablative high dose chemotherapy with autologous stem-cell rescue (HDT) and those not (NoHDT). Materials and methods: Relevant information was extracted from individual patient or summary data and 3-year EFS and OS rates established. These rates were combined in a weighted manner to derive hazard ratios (HRs). Results: Nineteen publications were identified (5 HDT, 6 NoHDT, 8 both). Pooling all studies suggested an advantage to HDT with a hazard ratio (HR) for EFS of 0.87 (95% confidence interval (CI) 0.67-1.12) and 0.94 (0.71-1.24) for OS. A stratified analysis confined to studies that provided individual patient data on both HDT and NoHDT gave HRs of 0.83 (0.56-1.24) and 0.92 (0.59-1.41). Further, analyses of risk groups, defined by treatment and/or histology prior to first relapse, suggested a HR for EFS of 0.90 (95% CI 0.62-1.31) for those of high and 0.50 (CI 0.31-0.82) for the very high risk patients. Conclusion: The evidence suggests, although there are many caveats since the information summarised here is not from randomised trials, a great deal of uncertainty concerning the role of HDT in patients following relapse after treatment for their Wilms' tumour. For each risk group we propose a randomised trial comparing a standard with a more intensive therapy with specific choice of regimen tailored to the risk group (and co-operative groups) concerned. A synthesis of updated evidence from studies in this overview together with any emerging studies and future trial information will form the basis for future evidence-based clinical decision-making.

KW - High dose chemotherapy

KW - Relapsed Wilms' tumour

KW - Wilms' tumour

UR - http://www.scopus.com/inward/record.url?scp=84871435281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871435281&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2012.07.010

DO - 10.1016/j.ejca.2012.07.010

M3 - Article

C2 - 22959164

AN - SCOPUS:84871435281

VL - 49

SP - 194

EP - 210

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 1

ER -